Senior Associate Scientist (contract), Research
VaxcyteHighlight
Summary
About the Role
About You
- BS in Biochemistry, Molecular Biology, or a relevant science with a minimum of 5 years of relevant industry experience, or MS with a minimum of 3 years of relevant industry experience.
- Experience with diverse protein targets, including bacterial and eukaryotic recombinant proteins, small/large subunit vaccine antigens, fusion proteins, multimeric complexes, glycoproteins, and VLPs.
- Experience with cell-free protein synthesis systems.
- Familiarity with automation or high throughput workflows such as 96-well plates and UNICORN/AKTA software DoE integrations.
- Experience in process development.
Benefits
- Competitive hourly rate ranging from $56.00 to $62.00.
- Opportunity to work in a clinical-stage vaccine innovation company.
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice. We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.